Abstract
The practice of statistics in the pharmaceutical industry has changed markedly over the last 25 years. This paper examines the evolution of clinical trial statistics in relationship to advances in statistical methodology and computational power as well as the changing regulatory environment. The current role of the biopharmaceutical statistician is assessed along with the drivers for future change.
Original language | American English |
---|---|
Journal | Journal of Biopharmaceutical Statistics |
Volume | 11 |
DOIs | |
State | Published - 2001 |
Keywords
- FDA
- Pharmaceutical industry
- Regulation
DC Disciplines
- Public Health
- Biostatistics